| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
|
Suzuki, Eiichiro
|
|
2013
|
71 |
5 |
p. 1141-1146
|
article
|
| 2 |
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer
|
Ramnath, N.
|
|
2013
|
71 |
5 |
p. 1173-1182
|
article
|
| 3 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
|
Plummer, Ruth
|
|
2013
|
71 |
5 |
p. 1191-1199
|
article
|
| 4 |
A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
|
Capdevila, J.
|
|
2013
|
71 |
5 |
p. 1247-1254
|
article
|
| 5 |
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies
|
Chow, Laura Q. M.
|
|
2013
|
71 |
5 |
p. 1273-1285
|
article
|
| 6 |
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer
|
Yunokawa, Mayu
|
|
2013
|
71 |
5 |
p. 1369-1374
|
article
|
| 7 |
A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation
|
Kolli, Viswa Kalyan
|
|
2013
|
71 |
5 |
p. 1209-1218
|
article
|
| 8 |
A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis
|
Abolmaali, Samira Sadat
|
|
2013
|
71 |
5 |
p. 1115-1130
|
article
|
| 9 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
|
Serova, Maria
|
|
2013
|
71 |
5 |
p. 1297-1307
|
article
|
| 10 |
Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
|
Lee, Soo Jung
|
|
2013
|
71 |
5 |
p. 1201-1207
|
article
|
| 11 |
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
|
Gozgit, Joseph M.
|
|
2013
|
71 |
5 |
p. 1315-1323
|
article
|
| 12 |
Dodging a dogma: is treating beyond progression beneficial?
|
Naing, Aung
|
|
2013
|
71 |
5 |
p. 1385-1386
|
article
|
| 13 |
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
|
Sudo, Makoto
|
|
2013
|
71 |
5 |
p. 1325-1334
|
article
|
| 14 |
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro
|
Rigalli, Juan Pablo
|
|
2013
|
71 |
5 |
p. 1335-1343
|
article
|
| 15 |
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors
|
Saif, M. W.
|
|
2013
|
71 |
5 |
p. 1345-1355
|
article
|
| 16 |
Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution
|
Liu, Zhenzhen
|
|
2013
|
71 |
5 |
p. 1131-1139
|
article
|
| 17 |
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis
|
Fushida, S.
|
|
2013
|
71 |
5 |
p. 1265-1272
|
article
|
| 18 |
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer
|
Rinehart, John
|
|
2013
|
71 |
5 |
p. 1375-1383
|
article
|
| 19 |
Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer
|
Tsuburaya, Akira
|
|
2013
|
71 |
5 |
p. 1309-1314
|
article
|
| 20 |
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
|
Chan, Jennifer A.
|
|
2013
|
71 |
5 |
p. 1241-1246
|
article
|
| 21 |
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice
|
Pawaskar, Dipti K.
|
|
2013
|
71 |
5 |
p. 1219-1229
|
article
|
| 22 |
Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer
|
Zhao, Wan
|
|
2013
|
71 |
5 |
p. 1287-1295
|
article
|
| 23 |
Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts
|
Rocchetti, Maurizio
|
|
2013
|
71 |
5 |
p. 1147-1157
|
article
|
| 24 |
Principles of dose finding studies in cancer: a comparison of trial designs
|
Jaki, Thomas
|
|
2013
|
71 |
5 |
p. 1107-1114
|
article
|
| 25 |
Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel
|
Wu, Hao
|
|
2013
|
71 |
5 |
p. 1159-1171
|
article
|
| 26 |
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
|
Layman, Rachel M.
|
|
2013
|
71 |
5 |
p. 1183-1190
|
article
|
| 27 |
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1
|
Zhai, Jing-Ming
|
|
2013
|
71 |
5 |
p. 1255-1264
|
article
|
| 28 |
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
|
Pawaskar, Dipti K.
|
|
2013
|
71 |
5 |
p. 1231-1240
|
article
|
| 29 |
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
|
O’Connor, Robert
|
|
2013
|
71 |
5 |
p. 1357-1368
|
article
|
Journal description